Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia (COQ10)

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older

This study is being done to gather data on whether oral supplementation of CoQ10 is enriched in the blood and muscles in older adults with sarcopenia. This study involves 28 consecutive days of oral CoQ10 supplementation to explore changes in muscle strength, aerobic capacity and physical function with CoQ10 supplementation.

Study Overview

• Status: Withdrawn
• Conditions: Sarcopenia
• Intervention / Treatment: Other: Placebo; Drug: BPM31510

• Study Type: Interventional
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Orlando, Florida, United States, 32804
      • AdventHealth Translational Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years to 90 years (Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Participant must be male or female, ages 65 through 90 years of age.
2. Participant must be sedentary, defined as ≤ 1 structured intentional continuous exercise session (approximately 30 mins) per week.
3. Participant must be sarcopenic, defined as having a skeletal muscle mass index (SMI) of <7.25 kg/m2 for males or <5.67 kg/m2 for females via DEXA scan.
4. Participant states willingness to follow the protocol as described and will complete any forms needed throughout the study.
5. Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.

Exclusion Criteria:

1. Inability and/or unwillingness to comply with the protocol as written
2. Participant has had a significant cardiovascular event (e.g., myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure; or participant has evidence of cardiovascular disease assessed during the ECG at screening. In the event of a positive stress test, participants are referred to their primary care physician. If the electrocardiogram (ECG) is determined to be a false positive, participant may be allowed to participate in study after confirmatory records obtained.
3. The presence of any condition which contraindicate moderate exercise and would result in the inability to comply with the protocol as written or would compromise participant safety or data integrity, will be considered on a case-by-case basis by the Principal investigator and the study physician.
4. Participant is actively pursuing weight loss and/or lifestyle changes.
5. History of gastrointestinal or intracranial hemorrhage.
6. History of stroke or cerebrovascular accident.
7. Participant has diabetes.
8. Weight stable -no gain/loss by self-report of ≥ 10 lbs in 6 months prior to screening
9. BMI 40.0 kg/m2
10. Untreated or poorly controlled hypertension (SBP 150, DBP 95), or hypotension (SBP 100 DBP 60)
11. Participant has untreated hyperthyroidism (TSH (0.5mIU/L) or untreated hypothyroidism (TSH 10mIU/L).
12. Participant has current infection (requiring prescription antimicrobial or antiviral medication, or hospitalization), or corticosteroid treatment (with the exception of inhaled or topical steroids) in the last 3 months prior to screening visit.
13. Participant is currently taking anti-inflammatory medication or has had anti-inflammatory medication within 1 week prior to screening (including over the counter formulations, e.g., Aleve, Motrin, ibuprofen, naproxen, low dose aspirin).
14. Participant has had surgery requiring > 2 days of hospitalization in the last 1 month prior to screening visit.
15. Participant has an active malignancy or autoimmune disease.
16. Participant has current significantly impaired liver function in the opinion of the study Medical Investigator (mild asymptomatic fatty liver is acceptable), or hepatic enzyme tests are ≥ 2.5 times normal limit.
17. Participant has a chronic, contagious, or infectious diseases, such as active tuberculosis, Hepatitis B or C, or HIV, per self-report.
18. Participant currently has uncontrolled severe diarrhea, nausea or vomiting.
19. Participant has an obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel syndrome or other forms of gastrointestinal disease such as stage III or above gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis and bariatric surgery.
20. Participant has a mini-Mental State Examination score < 21.
21. Unable to participate in DXA assessments due to physical limitations of equipment tolerances (e.g., DXA 450-pound weight limit), claustrophobia, or based on Investigator's judgment at screening.
22. Participant has a sensitivity or allergy to lidocaine.
23. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.
24. Participant has peripheral vascular disease.
25. Participant has proteinuria defined as > 1+; approximately 30 mg/dl.
26. Clinically significant abnormality on ECG

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Older adults with sarcopenia (placebo)	Other: Placebo; A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
Active Comparator: Older adults with sarcopenia (drug)	Drug: BPM31510; A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of skeletal muscle	We will evaluate changes in mitochondrial function (respiration) on permeabilized skeletal muscle fiber bundles obtained from biopsies of the vastus lateralis and blood draws, respectively. Blood and muscle biospecimens will also be obtained for multi-omics analysis.	Following 28 days of treatment
Measurement of platelet CoQ10 level	We will evaluate changes in mitochondrial function (respiration) on cells (platelets) obtained from biopsies of the vastus lateralis and blood draws, respectively. Blood and muscle biospecimens will also be obtained for multi-omics analysis.	Following 28 days of treatment

Collaborators and Investigators

• Sponsor: AdventHealth Translational Research Institute
• Investigators: Principal Investigator: Paul Coen, PhD, AdventHealth Translational Research Institute

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2023
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: July 13, 2021
• First Submitted That Met QC Criteria: August 3, 2021
• First Posted (Actual): August 10, 2021

Study Record Updates

• Last Update Posted (Estimated): July 24, 2023
• Last Update Submitted That Met QC Criteria: July 21, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Sarcopenia
• Other Study ID Numbers: 1665113

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No